Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.57 |
| ▸ | MEN1 | O00255 | 2/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | L3MBTL3 | Q96JM7 | 3/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.51 |
| ▸ | MBTD1 | Q05BQ5 | 1/20 | 0.51 |
| ▸ | TP53BP1 | Q12888 | 1/20 | 0.51 |
| ▸ | L3MBTL4 | Q8NA19 | 1/20 | 0.51 |
| ▸ | HRH3 | Q9Y5N1 | 7/20 | 0.47 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | HRH1 | P35367 | 1/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.42 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5209386 | 0.84 | KMT2A (0.57) | KMT2AMEN1ALDH1A1MAPTL3MBTL3 | |
| SCHEMBL3767570 | 0.84 | KMT2A (0.55) | KMT2AMEN1ALDH1A1MAPTL3MBTL3 | |
| SCHEMBL4036039 | 0.84 | L3MBTL3 (0.48) | KMT2AMEN1ALDH1A1MAPTL3MBTL3 | |
| SCHEMBL4034760 | 0.83 | KMT2A (0.51) | KMT2AMEN1ALDH1A1MAPTHRH3 | |
| SCHEMBL3968371 | 0.83 | KMT2A (0.74) | KMT2AMEN1ALDH1A1MAPTL3MBTL3 | |
| Hydrochloric Acid SCHEMBL5213050 | 0.83 | KMT2A (0.56) | KMT2AMEN1ALDH1A1MAPTL3MBTL3 | |
| SCHEMBL4035015 | 0.83 | HRH3 (0.53) | KMT2AMEN1ALDH1A1MAPTL3MBTL3 | |
| SCHEMBL3773944 | 0.82 | KMT2A (0.55) | KMT2AMEN1ALDH1A1MAPTL3MBTL3 | |
| SCHEMBL4031778 | 0.82 | HRH3 (0.66) | ALDH1A1MAPTHRH3NPC1RAB9A | |
| SCHEMBL4427879 | 0.82 | KMT2A (0.57) | KMT2AMEN1ALDH1A1MAPTL3MBTL3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1789410-B1 | METHYLENE DIPIPERIDINE DERIVATIVES | GLAXO GROUP LTD (GB) | 2009-06-17 | — | — | EP | claimed |
| US-20080108624-A1 | Methylene Dipiperidine Derivatives | GLAXO GROUP LIMITED (GB) | 2008-05-08 | — | — | US | claimed |
| US-7638631-B2 | Methylene dipiperidine derivatives | GLAXO GROUP LIMITED (GB) | 2009-12-29 | — | — | US | disclosed |
| US-7638631-B2 | Methylene dipiperidine derivatives | GLAXO GROUP LIMITED (GB) | 2009-12-29 | — | — | US | disclosed |
| US-7638631-B2 | Methylene dipiperidine derivatives | GLAXO GROUP LIMITED (GB) | 2009-12-29 | — | — | US | disclosed |
| EP-1789410-B1 | METHYLENE DIPIPERIDINE DERIVATIVES | GLAXO GROUP LTD (GB) | 2009-06-17 | — | — | EP | disclosed |
| EP-1789410-B1 | METHYLENE DIPIPERIDINE DERIVATIVES | GLAXO GROUP LTD (GB) | 2009-06-17 | — | — | EP | disclosed |
| US-20080108624-A1 | Methylene Dipiperidine Derivatives | GLAXO GROUP LIMITED (GB) | 2008-05-08 | — | — | US | disclosed |
| US-20080108624-A1 | Methylene Dipiperidine Derivatives | GLAXO GROUP LIMITED (GB) | 2008-05-08 | — | — | US | disclosed |
| US-20080108624-A1 | Methylene Dipiperidine Derivatives | GLAXO GROUP LIMITED (GB) | 2008-05-08 | — | — | US | disclosed |
| EP-1789410-A1 | METHYLENE DIPIPERIDINE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2007-05-30 | — | — | EP | disclosed |
| WO-2006029906-A1 | METHYLENE DIPIPERIDINE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2006-03-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080108624-A1 | Methylene Dipiperidine Derivatives | DRD2, DRD4, PNMT | KMT2A 713/4885MEN1 3050/4885ALDH1A1 1390/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.